Education
About Us
Working with TipRanks
Follow Us
Xbrane Biopharma AB (SE:XBRANE)
:XBRANE
XBRANE Stock Chart & Stats
kr15.00
>-kr0.01(-2.10%)
At close: 4:00 PM EST
kr15.00
>-kr0.01(-2.10%)
Day’s Range― - ―
52-Week Rangekr13.20 - kr38.33
Previous CloseN/A
Volume1.93M
Average Volume (3M)117.17K
Market Cap
€309.08M
Enterprise Valuekr406.95M
Total Cash (Recent Filing)€5.86M
Total Debt (Recent Filing)€20.00M
Price to Earnings (P/E)2.3
Beta1.42
Next Earnings
Oct 24, 2025EPS Estimate
1.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.81
Shares Outstanding20,605,349
10 Day Avg. Volume189,097
30 Day Avg. Volume117,165
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.55Price Target Upside-96.31% Downside
Rating ConsensusHold
Number of Analyst Covering0
Xbrane Biopharma AB News
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr13.20 and its highest was kr38.33 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is €309.08M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is Oct 24, 2025 which is in 3 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Aug 26, 2025. The company reported kr13.812 earnings per share for the quarter, the consensus estimate of kr13.812 by kr0.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate is 1.59.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of kr13.812 in its last earnings report, expectations of kr13.812. Following the earnings report the stock price went down -10.653%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (XBRANE) is a biotechnology company focused on the development and commercialization of high-quality biosimilars, primarily in the field of monoclonal antibodies. The company is headquartered in Sweden and operates within the biopharmaceutical sector, aiming to offer cost-effective alternatives to expensive biological therapies for various diseases, including cancer and autoimmune disorders. Xbrane's core products include its proprietary biosimilar candidates, which are designed to replicate the efficacy and safety of existing biologic drugs.
Technical Analysis
Ascelia Pharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Active Biotech AB
―
Immunicum AB
―